Janux Therapeutics (NASDAQ:JANX) Now Covered by UBS Group

UBS Group assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a research note published on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $69.00 price target on the stock.

Several other equities research analysts have also commented on the company. Scotiabank cut their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research report on Monday, September 16th. Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a research note on Monday, August 19th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $66.44.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $53.41 on Thursday. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of -43.78 and a beta of 3.54. Janux Therapeutics has a 52-week low of $5.65 and a 52-week high of $65.60. The firm has a 50 day moving average price of $47.10 and a two-hundred day moving average price of $46.00.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. The company’s revenue was up 709.1% on a year-over-year basis. As a group, equities research analysts predict that Janux Therapeutics will post -1.18 EPS for the current fiscal year.

Insider Activity

In other news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the completion of the sale, the chief executive officer now directly owns 307,054 shares of the company’s stock, valued at $14,219,670.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the transaction, the chief executive officer now owns 307,054 shares of the company’s stock, valued at $14,219,670.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the sale, the insider now directly owns 3,162,851 shares of the company’s stock, valued at $132,839,742. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 395,610 shares of company stock worth $17,950,166 over the last three months. 35.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Summit Securities Group LLC purchased a new stake in Janux Therapeutics in the 2nd quarter valued at about $29,000. Amalgamated Bank increased its position in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Janux Therapeutics in the second quarter worth $151,000. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.